Physician profile
Sujan Joshi
NPI 1073741732
$3,910.00
in general payments reported to CMS, 2019-2025
27 companies · $1,275 in 2025
The $1,275 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $277 · 2020: $99.08 · 2022: $776 · 2023: $707 · 2024: $775 · 2025: $1,275.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,757.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,757.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $590.28 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $520.91 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $481.54 | 2022-2025 | |
| Glaxosmithkline, LLC. | $392.60 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $273.69 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $262.50 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $213.17 | 2019-2025 | Airsupra, Breztri |
| Astellas Pharma US INC | $213.17 | 2019-2025 | Veozah |
| Amgen INC. | $188.54 | 2019-2025 | Otezla, Repatha, Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.63 | 2019-2025 | Jardiance, Ofev |
| Biohaven Pharmaceutical Holding Company LTD. | $81.05 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $68.77 | 2024-2025 | Rexulti |
| Exact Sciences Corporation | $63.40 | 2023-2025 | Cologuard Collection Kit |
| Corium, LLC | $60.53 | 2024-2025 | Azstarys |
| Merck Sharp & Dohme LLC | $40.27 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $38.24 | 2023-2024 | Dexcom G6 Transmitter |
| Smith+Nephew, INC. | $35.62 | 2020-2022 | |
| Abbott Laboratories | $35.00 | 2023 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $31.31 | 2022-2023 | |
| Currax Pharmaceuticals LLC | $30.99 | 2024 | Onzetra Xsail, Contrave |
| Janssen Pharmaceuticals, INC | $30.96 | 2023 | Xarelto |
| Kowa Pharmaceuticals America, INC. | $29.47 | 2025 | Zoryve |
| Biogen, INC. | $23.44 | 2024 | Skyclarys |
| Scynexis, INC. | $22.43 | 2022 | |
| Mylan Specialty L.P. | $21.57 | 2024 | Yupelri |
| Novartis Pharmaceuticals Corporation | $20.02 | 2022 | |
| Therapeuticsmd, INC. | $18.90 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sujan Joshi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.